Targeting of two aspects of metabolism in breast cancer treatment

por Gang, Bevan P, Dilda, Pierre J, Hogg, Phillip J, Blackburn, Anneke C
Publicado 2014

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resect...

por Heinemann, V, Ebert, M P, Laubender, R P, Bevan, P, Mala, C, Boeck, S
Publicado 2013

In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance

por Mistry, P, Plumb, J, Eccles, S, Watson, S, Dale, I, Ryder, H, Box, G, Charlton, P, Templeton, D, Bevan, P B
Publicado 1999

Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.

por Dale, I. L., Tuffley, W., Callaghan, R., Holmes, J. A., Martin, K., Luscombe, M., Mistry, P., Ryder, H., Stewart, A. J., Charlton, P., Twentyman, P. R., Bevan, P.
Publicado 1998

Accounting for the Impact of Conservation on Human Well-Being

por Milner-Gulland, EJ, Mcgregor, JA, Agarwala, M, Atkinson, G, Bevan, P, Clements, T, Daw, T, Homewood, K, Kumpel, N, Lewis, J, Mourato, S, Palmer Fry, B, Redshaw, M, Rowcliffe, JM, Suon, S, Wallace, G, Washington, H, Wilkie, D
Publicado 2014